Back to Journals » OncoTargets and Therapy » Volume 13

Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers

Authors Han W, Shi J, Cao J, Dong B, Guan W

Received 6 March 2020

Accepted for publication 11 June 2020

Published 1 July 2020 Volume 2020:13 Pages 6393—6403

DOI https://doi.org/10.2147/OTT.S252750

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Leo Jen-Liang Su


Wei Han, Jia Shi, Jiachao Cao, Bo Dong, Wei Guan

Department of Neurosurgery, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of China

Correspondence: Wei Guan No. 185, Juqian Street, Changzhou, Jiangsu 213003, People’s Republic of China
Email guanwei1402@163.com

Abstract: Long non-coding RNAs (lncRNAs) have been potent regulators in the initiation and development of human cancers regarding their biological roles in the modulation of dosage compensation effect, epigenetics and cell differentiation. Recently, aberrant expression of lncRNA small nucleolar RNA host gene 5 (SNHG5) has been observed in various solid tumors, which was intently correlated with tumor range, metastasis, pathological stage and prognosis. Additional mechanical investigation disclosed that SNHG5 was involved in multiple cellular activities, including proliferation, migration, invasion, cell-cycle, apoptosis and autophagy, via targeting miRNAs, signaling pathways and other biological molecules or proteins. In this review, we summarized the latest advances made towards understanding the roles of SNHG5 in human cancers and further discussed potential methods that could be adopted for clinical interventions.

Keywords: lncRNA, SNHG5, biomarker, therapeutic target, human cancers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]